Lecturer on Law
Nisa Leung is a Managing Partner of Qiming Venture Partners, leading its health care investments. Qiming Venture Partners is a leading investment firm in China which currently manages seven USD funds and five RMB funds with USD 4.3 billion in assets and investment in over 310 companies.
She currently sits on the board of Gan & Lee Pharmaceutical, Zai Lab (NASDAQ: ZLAB), Venus MedTech, Nurotron, Goodwill Information Technology, dMed, CanSino Biologics (HKSE: 6185), New Horizon Bio and Berry Oncology. Her other investments include Acea Biosciences (diagnostic division acquired by Agilent), Aeonmed Medical, Berry Genomics (SZSE:000710), CITIC Pharmaceuticals (acquired by Shanghai Pharmaceutical HKSE: 02607), Crown Bioscience (acquired by JSR Life Sciences), Novast Pharmaceuticals, Origene Technologies (acquired by VCAN Bio SHSE: 600645), Richen, Wuxi Leiming, Chain Medical Labs, Suzhou Qiagen, Cure Genetics, SinoCell Tech, Jacobio and Schrodinger among others.
Nisa has been recognized by the Forbes Global 100 VC Midas List in 2019, named Top 3 Best Female Venture Capitalist in China by Forbes in 2018 and won Venture Capital Professional of the Year by Asian Venture Capital Journal in 2017.
Nisa earned her MBA from Stanford Graduate School of Business and a BS from Cornell University. She is currently a founding vice chair of PhIRDA Investment Committee, member of Committee on Hong Kong Innovation and Technology Development and Re-Industrialization, advisor of Our Hong Kong Foundation, founder of Venture Investors Alliance of Hong Kong and council member of HKUST Business School. She also serves on the Board of Trustees of the Hotchkiss School and board member of the Hong Kong Palace Museum.